HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+16.91%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$276M
AUM Growth
+$276M
(+28%)
Cap. Flow
+$45.5M
Cap. Flow
% of AUM
16.5%
Top 10 Holdings %
Top 10 Hldgs %
29.49%
Holding
157
New
25
Increased
65
Reduced
12
Closed
31
Top Buys
| 1 |
Spyre Therapeutics
SYRE
|
$12.4M |
| 2 |
HES
Hess
HES
|
$4.17M |
| 3 |
SOVO
Sovos Brands, Inc. Common Stock
SOVO
|
$4.07M |
| 4 |
SP
SP Plus Corporation
SP
|
$4.04M |
| 5 |
UiPath
PATH
|
$3.07M |
Top Sells
Sector Composition
| 1 | Healthcare | 45.71% |
| 2 | Technology | 11.75% |
| 3 | Consumer Discretionary | 6.51% |
| 4 | Industrials | 5.31% |
| 5 | Consumer Staples | 4.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.27B
| $31.7M | 11.49% | 1,436,136 | – | – |
|
|
2
Spyre Therapeutics
SYRE
$996M
| $12.4M | 4.51% | +577,616 | New | +$12.4M |
|
3
Microsoft
MSFT
$3.77T
| $5.44M | 1.97% | 14,458 +4,500 | +45% | +$1.69M |
|
4
Immunovant
IMVT
$2.56B
| $5.11M | 1.85% | 121,287 +14,379 | +13% | +$606K |
|
5
Axsome Therapeutics
AXSM
$6.05B
| $4.96M | 1.8% | 62,263 +5,299 | +9% | +$422K |
|
6
IDEAYA Biosciences
IDYA
$2.15B
| $4.51M | 1.64% | 126,845 | – | – |
|
7
Albertsons Companies
ACI
$10.9B
| $4.34M | 1.58% | 188,753 | – | – |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $4.32M | 1.57% | 198,484 +93,728 | +89% | +$2.04M |
|
|
IMGN
9
DELISTED
Immunogen Inc
IMGN
| $4.29M | 1.56% | 144,772 | – | – |
|
|
SPLK
10
DELISTED
Splunk Inc
SPLK
| $4.2M | 1.53% | 27,600 | – | – |
|
|
HES
11
DELISTED
Hess
HES
| $4.17M | 1.51% | +28,900 | New | +$4.17M |
|
|
CERE
12
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $4.12M | 1.5% | 97,200 +72,313 | +291% | +$3.07M |
|
|
SOVO
13
DELISTED
Sovos Brands, Inc. Common Stock
SOVO
| $4.07M | 1.48% | +184,600 | New | +$4.07M |
|
|
SP
14
DELISTED
SP Plus Corporation
SP
| $4.04M | 1.47% | +78,900 | New | +$4.04M |
|
15
Arcellx
ACLX
$3.85B
| $4.01M | 1.45% | 72,230 -5,798 | -7% | -$322K |
|
16
Nuvalent
NUVL
$5.52B
| $3.98M | 1.44% | 54,083 | – | – |
|
17
Salesforce
CRM
$245B
| $3.94M | 1.43% | 14,979 +4,500 | +43% | +$1.18M |
|
18
Insmed
INSM
$28.8B
| $3.93M | 1.43% | 126,780 +46,780 | +58% | +$1.45M |
|
19
Capri Holdings
CPRI
$2.45B
| $3.9M | 1.42% | 77,700 | – | – |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| $3.79M | 1.37% | 160,334 -19,971 | -11% | -$472K |
|
|
AMED
21
DELISTED
Amedisys
AMED
| $3.73M | 1.35% | 39,250 | – | – |
|
22
Merus
MRUS
$4.98B
| $3.67M | 1.33% | 133,572 +10,941 | +9% | +$301K |
|
23
MoonLake Immunotherapeutics
MLTX
$3.54B
| $3.61M | 1.31% | 59,769 | – | – |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $3.48M | 1.26% | 247,880 | – | – |
|
25
Visa
V
$683B
| $3.21M | 1.16% | 12,327 +3,600 | +41% | +$937K |
|